Keywords: globeimmune, tarmogen, plus, soc, shows, evr, 12-week
GlobeImmune's Tarmogen plus SOC shows 94% EVR
Article | 24 April 2009
12-week Phase II trial data show that patients treated with GI-5005, GlobeImmune's targeted molecular Tarmogen (immunogen) for hepatitis C virus ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
